Biosimilars are biologic medications that are highly similar to existing biologic medicines in terms of safety, efficacy, and quality, but are often more affordable. They are crucial in modern healthcare because they provide patients with cost-effective alternatives to biologic medications, increasing accessibility to vital treatments.

At Teva, we leverage our expertise in both high-quality complex generics and innovative medicines as well as partnering with leading developers to offer a wide range of high-quality biosimilars. This focus on biosimilars is a natural progression for us after leading the generic medicine industry for over 40 years.

We deliver biosimilars that meet rigorous regulatory standards and are highly similar to their reference biologic medication. Our comprehensive approach includes clinical research, robust quality control, and ongoing monitoring to ensure safety and efficacy to the highest standard.

Our Teva biosimilar portfolio covers a wide range of therapeutic areas, including oncology, autoimmune diseases, and other complex conditions. By offering high-quality biosimilars, we aim to contribute to a more sustainable healthcare system.

Teva’s dedication to biosimilars extends beyond product development. We educate healthcare professionals and patients about the importance of biosimilars and actively promote their acceptance and use. Additionally, we collaborate with healthcare organizations, regulatory bodies, and industry leaders to advance biosimilar development and adoption.

NPS-ALL-NP-01501 MARCH 2025